Jean-Baptiste E, Hassen-Khodja R, Bouillanne P-J, Haudebourg P, Declemy S, Batt M
Department of Vascular Surgery, University Hospital of Nice, Nice, France.
Eur J Vasc Endovasc Surg. 2007 Aug;34(2):145-51. doi: 10.1016/j.ejvs.2007.02.023. Epub 2007 May 7.
Following the publication of a prospective randomized trial (EVAR2) that questioned the benefit of endovascular repair of abdominal aortic aneurysms (AAA) for high-surgical-risk patients, we evaluated our own initial and long-term results with endovascular AAA repair for this patient population.
Between January 2000 and December 2005, 115 patients with an AAA managed by an aortic endograft were entered in a registry. Data concerning diagnosis, operative risk, treatment, and follow-up were analyzed on an intention-to-treat basis for all patients considered to be poor candidates for surgery. Patients with a ruptured AAA and those who were good surgical candidates were excluded from analysis. The main goal was evaluation of the operative mortality and the long-term survival of these patients. Secondary goals were determination of the frequency of secondary operations, the outcome of the aneurysm sac, and primary and secondary patency rates after aortic endograft placement.
A total of 92 high-surgical-risk patients treated by an endograft were entered in this study. Sixty-seven patients (73%) were classed ASA III and 18 (20%) were ASA IV (20%). Mean aneurysm diameter was 58 mm+/-9 mm. The technical success rate was 99%. Operative mortality was 4.3% (4 cases). Four patients required re-intervention during the mean follow-up of 18 months. The survival rate at 3 yr was 85%. One type I endoleak (1%) and 9 type II endoleaks (9.7%) occurred during the follow-up period. Primary and secondary patency rates at 3 yr were respectively 96% and 100%.
Our initial and long-term results with endograft repair of AAA in high-surgical-risk patients were satisfactory. These results appear to justify endovascular repair for this patient population.
在一项前瞻性随机试验(EVAR2)发表后,该试验对腹主动脉瘤(AAA)血管内修复术对高手术风险患者的益处提出质疑,我们评估了我们自己对这一患者群体进行腹主动脉瘤血管内修复的初始和长期结果。
2000年1月至2005年12月,115例接受主动脉内移植物治疗的腹主动脉瘤患者被纳入登记系统。对所有被认为手术风险高的患者,基于意向性分析对诊断、手术风险、治疗和随访数据进行分析。破裂性腹主动脉瘤患者和手术风险低的患者被排除在分析之外。主要目标是评估这些患者的手术死亡率和长期生存率。次要目标是确定二次手术的频率、瘤囊的转归以及主动脉内移植物置入后的原发性和继发性通畅率。
本研究共纳入92例接受内移植物治疗的高手术风险患者。67例(73%)患者美国麻醉医师协会(ASA)分级为III级,18例(20%)为ASA IV级(20%)。平均动脉瘤直径为58 mm±9 mm。技术成功率为99%。手术死亡率为4.3%(4例)。在平均18个月的随访期间,4例患者需要再次干预。3年生存率为85%。随访期间发生1例I型内漏(1%)和9例II型内漏(9.7%)。3年时原发性和继发性通畅率分别为96%和100%。
我们对高手术风险患者进行腹主动脉瘤内移植物修复的初始和长期结果令人满意。这些结果似乎证明了对这一患者群体进行血管内修复是合理的。